 Atlanta, Georgia--Newsfile Corp. - January 25, 2021 - Holzer Holzer, LLC is investigating whether Neoleukin Therapeutics, Inc. NASDAQ: NLTX Neoleukin or the Company complied with federal securities laws. On January 8, 2021, Neoleukin announced that on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration FDA related to its Investigational New Drug IND Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201.... 